我要投票 哈药牌在补铁锌硒行业中的票数:200
· 外 推 电 报 ·
2025-02-24 07:53:59 星期一

【哈药牌是哪个国家的品牌?】

哈药牌是什么牌子?「哈药牌」是 哈药集团有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人张利君在1989期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力哈药牌品牌出海!通过在本页面挂载哈药牌品牌的产品链接和联系邮箱,可以提高哈药牌产品曝光!跨境电商爆单神器,目前只要100元/年哦~

哈药集团制药总厂始建于1958年,经过半个世纪的艰苦创业,不懈追求,已经由名不见经传的简陋小厂发展成为国内拥有先进理念、科学管理、核心竞争力的大型综合性制药企业,位列全国医药“百强”企业之首。年销售收入近50亿元,出口创汇1亿多美元。

公司主要生产青霉素类、头孢菌素类、大环内酯类抗生素以及心脑血管用药等30种原料药、原料中间体和100多种制剂品种。青霉素工业盐和7ACA两大母核的技术质量指标始终处于国内领先、国际一流水平。

企业拥有技术装备先进、管理体系完善的科研开发中心、质量检验中心、计控中心及生产、销售、服务等系统和职能部门,拥有精干、专业、严谨、高效的管理团队和敬业、忠诚、团结、向上的员工队伍。

企业先后自行研制开发了三类新药凯兰欣、铃兰欣、头孢吡肟、头孢替唑等,四类新药头孢唑肟钠、盐酸头孢替安、、盐酸头孢他美酯等几十种新产品。头孢替安无菌原料药是国内独家品种,获得了省科技进步奖、国家重点新稆证书;头孢美唑工艺技术的攻关成果获得国家重点新产品证书和医药行业科技进步一等奖。

企业的主导产品青霉素、头孢菌素类原粉和制剂均通过国家药品监督管理局GMP认证;青霉素工业钾盐通过了美国FDA认证;部分原料药和制剂通过南非卫生部的GMP认证;头孢唑林钠、头孢曲松钠原料药通过欧洲EDMF认证。

哈药集团制药总厂是中国重点抗生素生产和出口基地。营销系统下设九个销售公司,在全国29个省分布有62个办事处、600余名销售业务员,拥有5600多个经销商,产品覆盖除港澳台以外的所有区县。国际贸易营销网络覆盖中东、东南亚、南美、印度、俄罗斯以及原独联体其它国家、非洲、欧盟等市场,产品远销40多个国家和地区。

“哈药”品牌在2010年中国最有价值的品牌评价中,价值已达到160.62亿元,成为中国医药行业之冠和黑龙江省第一品牌。哈药集团制药总厂是国家级重合同守信用单位,哈药产品以优质、高效、安全在广大客户和消费者心目中享有盛誉。

哈药集团制药总厂秉承“厚德载物、兢兢以强”的企业精神,始终以发展和壮大祖国医药事业、造福人类健康为已任,孜孜以求,矢志超越,全力打造中国最具科技实力、经营潜力、发展张力、文化魅力的规范化、现代化、国际化的医药界强企,努力为社会、为人类创造更大的价值。

英文翻译:Harbin Pharmaceutical Group Pharmaceutical General Factory was founded in 1958. After half a century of hard work and unremitting pursuit, it has developed from a humble small factory to a large comprehensive pharmaceutical enterprise with advanced concept, scientific management and core competitiveness, ranking first among the "top 100" pharmaceutical enterprises in China. The annual sales revenue is nearly 5 billion yuan, and the export income is more than 100 million US dollars. The company mainly produces 30 kinds of APIs, raw material intermediates and more than 100 kinds of preparation varieties, such as penicillin, cephalosporins, macrolides antibiotics and cardio cerebrovascular drugs. The technical quality indexes of penicillin industrial salt and 7aca are always at the leading level in China and the first-class level in the world. The company has scientific research and development center, quality inspection center, planning and control center, production, sales, service and other systems and functional departments with advanced technology and equipment and perfect management system, and has a capable, professional, rigorous and efficient management team and dedicated, loyal, United and upward staff team. The company has developed three kinds of new drugs, kailanxin, suzulanxin, cefepime, ceftizole, and dozens of new products, including four kinds of new drugs, ceftizoxime sodium, cefotiam hydrochloride, ceftazidime hydrochloride, etc. Ceftriaxone sterile API is an exclusive product in China, which has won the provincial science and Technology Progress Award and the national key new product certificate; the research achievements of ceftriaxone technology have won the national key new product certificate and the first prize of science and technology progress in the pharmaceutical industry. The leading products of the enterprise are penicillin, cephalosporin raw powder and preparations, which have passed GMP certification of the State Drug Administration; potassium salt of penicillin industry has passed FDA certification of the United States; some APIs and preparations have passed GMP certification of the Ministry of health of South Africa; cefazolin sodium and ceftriaxone sodium raw materials have passed edmf certification of Europe. Harbin Pharmaceutical Group Pharmaceutical General Factory is a key antibiotic production and export base in China. The marketing system consists of nine sales companies, 62 offices in 29 provinces, more than 600 salespeople, and more than 5600 distributors, covering all districts and counties except Hong Kong, Macao and Taiwan. The international trade marketing network covers the markets of the Middle East, Southeast Asia, South America, India, Russia, other countries of the former CIS, Africa, EU, etc. its products are exported to more than 40 countries and regions. In 2010, the most valuable brand evaluation in China, the value of "Harbin Pharmaceutical" brand has reached 16.062 billion yuan, becoming the top of China's pharmaceutical industry and the first brand in Heilongjiang Province. Harbin Pharmaceutical Group Pharmaceutical Factory is a state-level contract abiding and trustworthy unit. Harbin pharmaceutical products enjoy a high reputation in the eyes of customers and consumers for their high quality, efficiency and safety. Harbin Pharmaceutical Group Pharmaceutical General Factory adheres to the enterprise spirit of "being virtuous and hardworking and strong", and always takes the development and expansion of the pharmaceutical industry of the motherland and the benefit of human health as its responsibility. It strives to surpass and strive to build a standardized, modern and international pharmaceutical industry with the most scientific and technological strength, business potential, development tension and cultural charm in China, striving to be a society and a person Class creates greater value.

本文链接: https://www.waitui.com/brand/2c2f753da.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

2小时前

2025年中央一号文件发布

36氪获悉,2025年中央一号文件2月23日发布,《中共中央 国务院关于进一步深化农村改革 扎实推进乡村全面振兴的意见》提出,以改革开放和科技创新为动力,巩固和完善农村基本经营制度,深入学习运用“千万工程”经验,确保国家粮食安全,确保不发生规模性返贫致贫,提升乡村产业发展水平、乡村建设水平、乡村治理水平,千方百计推动农业增效益、农村增活力、农民增收入,为推进中国式现代化提供基础支撑,这是党的十八大以来第13个指导“三农”工作的中央一号文件。

2小时前

海天味业:公司发行H股备案申请材料获中国证监会接收

36氪获悉,海天味业公告称,公司已于2025年1月13日向香港联交所递交了发行H股股票并在香港联交所主板挂牌上市的申请。公司已向中国证监会报送了关于公司本次发行的备案申请材料并于近日获中国证监会接收。该事项仍存在不确定性,公司将根据进展情况及时履行信息披露义务。

2小时前

山河药辅:股东复星医药拟减持不超过3%公司股份

36氪获悉,山河药辅发布公告,股东上海复星医药产业发展有限公司因经营需要,计划以集中竞价和大宗交易方式合计减持公司股份不超过697.8万股,即不超过公司总股本的3%。

2小时前

镁伽科技正式推出LABILLION™实验室智慧管理平台,并于线上发布

36氪获悉,近日镁伽科技正式推出LABILLION™实验室智慧管理平台,并于线上发布。作为镁伽在“AI for Science(AI4S)”领域的新成果,LABILLION™以AI与自动化技术为核心,针对生命科学研发中长期存在的数据孤岛、系统僵化、流程低效等痛点,为科学家提供从实验设计到数据分析的全链路智能支持,助力科研创新效率的提升。

2小时前

本页详细列出关于全元康的品牌信息,含品牌所属公司介绍,全元康所处行业的品牌地位及优势。
咨询